Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 10, 2010, Pages 1623-1629

  Price, Katharine A ^a,c   Azzoli, Christopher G ^a   Krug, Lee M ^a   Pietanza, Maria C ^a   Rizvi, Naiyer A ^a   Pao, William ^a,d   Kris, Mark G ^a   Riely, Gregory J ^a   Heelan, Robert T ^b   Arcila, Maria E ^b   Miller, Vincent A ^a  

^a Division of Solid Tumor Oncology   (Italy)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MAYO CLINIC   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Everolimus; Gefitinib; Non small cell lung cancer

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EVEROLIMUS; GEFITINIB; GEMCITABINE; NAVELBINE; PEMETREXED; STEROID;

AGED; ANEMIA; ANOREXIA; ARTICLE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRY EYE; DRY SKIN; DYSGEUSIA; DYSPNEA; EPISTAXIS; EXON; FATIGUE; FEMALE; FEVER; GENE DELETION; GENE MUTATION; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPONATREMIA; HYPOPHOSPHATEMIA; INTERNATIONAL NORMALIZED RATIO; LEG EDEMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOCYTOPENIA; MALE; MOUTH ULCER; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SMOKING; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

EID: 77958161544     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ec1531     Document Type: Article

References (36)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500. (Pubitemid 38720929)
3. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311. (Pubitemid 39209661)
4. Paz-Ares L, Sanchez JM, Garcia-Velasco A, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 2006;24:7020.
5. Sequist LV, Martins RG, Spigel D, et al. iTARGET: a phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors. J Clin Oncol 2007;25:7504.
6. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-844. (Pubitemid 43259866)
7. Rodenhuis S, van de Wetering ML, Mooi WJ, et al. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987;317:929-935. (Pubitemid 17147935)
8. Suzuki Y, Orita M, Shiraishi M, et al. Detection of ras genemutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain-reaction products. Oncogene 1990;5:1037-1043. (Pubitemid 20220246)
9. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17. (Pubitemid 40412734)
10. Janmaat ML, Kruyt FA, Rodriguez JA, et al. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316-2326.
11. Kokubo Y, Gemma A, Noro R, et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 2005;92: 1711-1719. (Pubitemid 40756483)
12. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004;25:2053-2059. (Pubitemid 39534841)
13. Han S, Khuri FR, Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 2006;66:315-323. (Pubitemid 43166038)
14. Wislez M, Spencer ML, Izzo JG, et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 2005;65:3226-3235. (Pubitemid 40524605)
15. Molina JR, Mandrekar SJ, Rowland K, et al. A phase II NCCTG "Window of Opportunity Front-line" study of the mTOR inhibitor, CCI-779 (Temsirolimus) given as a single agent in patients with advanced NSCLC:D7-07. J Thorac Oncol 2007;2:S413.
16. Papadimitrakopoulou V, Soria JC, Douillard JY, et al. A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinumbased chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I). J Clin Oncol 2007;25:7589.
17. Milton DT, Riely GJ, Azzoli CG, et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 2007;110:599-605. (Pubitemid 47106149)
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
19. Wang X, Hawk N, Yue P, et al. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther 2008;7:1952-1958.
20. La Monica S, Galetti M, Alfieri RR, et al. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol 2009;78:460-468.
21. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366: 1527-1537. (Pubitemid 41540110)
22. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065-3074.
23. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-7058. (Pubitemid 41161231)
24. Wang X, Yue P, Kim YA, et al. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 2008;68:7409-7418.
25. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-1508. (Pubitemid 43259931)
26. Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008;122:2255-2259. (Pubitemid 351542328)
27. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005;436:792. (Pubitemid 41160630)
28. Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005;41:1649-1654. (Pubitemid 40981849)
29. Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFRamplified lung cancer. J Clin Invest 2006;116:2695-2706. (Pubitemid 44511633)
30. Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003;22:2812-2822. (Pubitemid 36609595)
31. Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009;69:3256-3261.
32. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
33. Catalogue of Somatic Mutations in Cancer (COSMIC) [database online]. Cambridge, UK: Wellcome Trust Sanger Institute, 2009. Updated September 18, 2006.
34. Cohen MH, Williams GA, Sridhara R, et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-306. (Pubitemid 36929716)
35. Soria JC, Shepherd FA, Douillard JY, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009;20:1674-1681.
36. Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006;42:1875-1880. (Pubitemid 44149096)